Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.7.2967

A New Tool to Predict Survival after Radiosurgery Alone for Newly Diagnosed Cerebral Metastases  

Rades, Dirk (Department of Radiation Oncology, Faculty of Medicine, University of Lubeck)
Huttenlocher, Stefan (Department of Radiation Oncology, Faculty of Medicine, University of Lubeck)
Dziggel, Liesa (Department of Radiation Oncology, Faculty of Medicine, University of Lubeck)
Blanck, Oliver (Department of Radiosurgery, CyberKnife Centre Northern Germany)
Hornung, Dagmar (Department of Radiation Oncology, Faculty of Medicine, University of Hamburg)
Mai, Khoa Trong (Department of Nuclear Medicine, Faculty of Medicine Hanoi Medical University)
Ngo, Trang Thuy (Department of Radiation Oncology, Nuclear Medicine and Oncology Center, Bach Mai Hospital)
Pham, Thai Van (Department of Radiation Oncology, Nuclear Medicine and Oncology Center, Bach Mai Hospital)
Schild, Steven (Department of Radiation Oncology, Mayo Clinic Scottsdale)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.7, 2015 , pp. 2967-2970 More about this Journal
Abstract
Many patients with few cerebral metastases receive radiosurgery alone. The goal of this study was to create a tool to estimate the survival of such patients. To identify characteristics associated with survival, nine variables including radiosurgery dose, age, gender, Eastern cooperative oncology group performance score (ECOG-PS), primary tumor type, number/size of cerebral metastases, location of cerebral metastases, extra-cerebral metastases and time between cancer diagnosis and radiosurgery were analyzed in 214 patients. On multivariate analysis, age (p=0.03), ECOG-PS (p=0.02) and extra-cerebral metastases (p<0.01) had significant impacts on survival. Scoring points for each patient were obtained from 12-month survival rates (in %) related to the significant variables divided by 10. Addition of the scoring points of the three variables resulted in a patient's total predictive score. Two groups were designed, A (10-14 points) and B (16-17 points). Twelve-month survival rates were 33% and 77%, respectively (p<0.001). Median survival times were 8 and 20 months, respectively. Because most patients of group A died from extra-cerebral disease and/or new cerebral lesions, early systemic treatment and additional WBI should be considered. As cause of death in group B was mostly new cerebral metastases, additional WBI appears even more important for this group.
Keywords
Cerebral metastases; radiosurgery alone; survival; prognostic factors; predictive tool;
Citations & Related Records
Times Cited By KSCI : 12  (Citation Analysis)
연도 인용수 순위
1 Akhavan A, Binesh F, Heidari S (2014). Survival of brain metastatic patients in Yazd, Iran. Asian Pac J Cancer Prev, 15, 3571-4.   DOI
2 Brown PD, Pugh S, Laack NN, et al (2013). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol, 15, 1429-37.   DOI   ScienceOn
3 Chindaprasirt J, Sookprasert A, Sawanyawisuth K, Limpawattana P, Tiamkao S (2012). Brain metastases from cholangiocarcinoma: a first case series in Thailand. Asian Pac J Cancer Prev, 13, 1995-7.   DOI
4 DeAngelis LM, Delattre JY, Posner JB (1989). Radiationinduced dementia in patients cured of brain metastases. Neurology, 39, 789-96.   DOI
5 Demircioglu F, Demirci U, Akmansu M (2013). Lymph node ratio assessment of brain metastasis in early breast cancer cases. Asian Pac J Cancer Prev, 14, 1665-7.   DOI
6 Duan L, Zeng R, Yang KH, et al (2014). Whole brain radiotherapy combined with stereotactic radiotherapy versus stereotactic radiotherapy alone for brain metastases: a meta-analysis. Asian Pac J Cancer Prev, 15, 911-5.   DOI   ScienceOn
7 Dziggel L, Segedin B, Podvrsnik NH, et al (2013). Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol, 189, 364-6.   DOI
8 Erten C, Demir L, Somali I, et al (2013). Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev, 14, 3711-7.   DOI
9 Hyun MK, Hwang JS, Kim JH, et al (2013). Survival outcomes after whole brain radiation therapy and/or stereotactic radiosurgery for cancer patients with metastatic brain tumors in Korea: a systematic review. Asian Pac J Cancer Prev, 14, 7401-7.   DOI   ScienceOn
10 Inamoto T, Azuma H, Nonomura N, et al (2014). Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka urologic oncology group. Asian Pac J Cancer Prev, 15, 1811-5.   DOI
11 Rades D, Panzner A, Dziggel L, et al (2012). Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer, 118, 3852-9.   DOI
12 Liu WJ, Zeng XT, Qin HF, et al (2012). Whole brain radiotherapy plus chemotherapy in the treatment of brain metastases from lung cancer: a meta-analysis of 19 randomized controlled trials. Asian Pac J Cancer Prev, 13, 3253-8.   DOI   ScienceOn
13 Lorenzoni J, Devriendt D, Massager N, et al (2004). Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys, 60, 218-24.   DOI
14 Mutlu H, Buyukcelik A, Erden A, et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6.   DOI   ScienceOn
15 Rades D, Dziggel L, Nagy V, et al (2013). A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiother Oncol, 108, 123-7.   DOI
16 Sun DS, Hu LK, Cai Y, et al (2014). A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1233-9.   DOI   ScienceOn
17 Vuong DA, Rades D, Le AN, Busse R (2012). The costeffectiveness of stereotactic radiosurgery versus surgical resection in the treatment of brain metastasis in Vietnam from the perspective of patients and families. World Neurosurg, 77, 321-8.   DOI
18 Vuong DA, Rades D, van Eck AT, Horstmann GA, Busse R (2013). Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: stereotactic radiosurgery versus surgical resection. Clin Neurol Neurosurg, 115, 276-84.   DOI
19 Yamamoto M, Sato Y, Serizawa T, et al (2012). Subclassification of recursive partitioning analysis class II patients with brain metastases treated radiosurgically. Int J Radiat Oncol Biol Phys, 83, 1399-1405.   DOI
20 Weltman E, Salvajoli JV, Brandt RA, et al (2000). Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys, 46, 1155-61.   DOI
21 Zeng YD, Zhang L, Liao H, et al (2012). Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev, 13, 909-14.   DOI   ScienceOn
22 Zhang JH, Wang MS, Pan HH, et al (2012). Correlation of CT perfusion images with VEGF expression in solitary brain metastases. Asian Pac J Cancer Prev, 13, 1575-8.   DOI